{
    "Trade/Device Name(s)": [
        "Borrelia B31 IgG ViraStripe",
        "Borrelia B31 IgG ViraStripe\u00ae"
    ],
    "Submitter Information": "Viramed Biotech AG",
    "510(k) Number": "K092693",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LSR"
    ],
    "Summary Letter Date": "August 31, 2009",
    "Summary Letter Received Date": "September 2, 2009",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.3830"
    ],
    "Regulation Name(s)": [
        "Treponema pallidum treponemal test reagents"
    ],
    "Analyte Class(es)": [
        "microbiology",
        "immunology"
    ],
    "Analyte(s)": [
        "IgG antibodies to Borrelia burgdorferi"
    ],
    "Specimen Type(s)": [
        "Human serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Qualitative assay",
        "Line blot"
    ],
    "Methodologies": [
        "Serological testing"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Viramed Biotech AG Borrelia B31 IgG ViraStripe qualitative assay for detection of IgG antibodies to Borrelia burgdorferi in human serum",
    "Indications for Use Summary": "Qualitative assay for detection of IgG antibodies to Borrelia burgdorferi in human serum, intended for testing samples positive or equivocal by EIA or IFA for supportive evidence of Lyme disease infection",
    "fda_folder": "Microbiology"
}